NCT00688688 (2013) Study to test the long-term safety and efficacy of the beta-3 agonist mirabegron (YM178) in patients with symptoms of overactive bladder (TAURUS). the site you are agreeing to our use of cookies. J Obstet Gynaecol Res. You can also search for this author in Pakistan Journal of Medical and Health Sciences. 2018;74(3):324–33. Manjunatha R, Pundarikaksha HP, Hanumantharaju BK, Anusha SJ. Eur Urol. Longer-term studies, with follow-up periods of up to a year, have also been reported. For more information view the Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is a common, distressing and often debilitating condition with a high prevalence in the general population. 2017;120(4):562–75.Herschorn S, Pommerville P, Stothers L, Egerdie B, Gajewski J, Carlson K, et al. BJU Int. Clinical Practice Guideline No. 2012;1:CD005429. 2018;29(2):273–83. 2009;15(4 Suppl):S98–s107.Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, et al. A patient’s preference for increased efficacy vs. reduced harms, and tolerance of specific adverse events, should be considered when selecting treatment for OAB.Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. World J Urol. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. 2015;9(3):FC05–9.NCT00431041 (2010) Study to compare the safety and efficacy of solifenacin with oxybutynin for the treatment of overactive bladder (VECTOR). 2003;13(4):285–91.Rai BP, Cody JD, Alhasso A, Stewart L (2012) Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, et al. 2002;21:167–78.Fantl J, Newman D, Colling J, DeLancey J, Keeys C, Loughery R, McDowell B, Norton P, Ouslander J, Schnelle J (1996) Urinary Incontinence in Adults: Acute and Chronic Management. Patients’ assessments of symptoms as measured by the OAB-q Symptom Bother score and/or the PPBC were in accordance with these numeric measures. In addition, expressions of muscarinic receptor subtypes (M 2 and M 3) were examined. Int J Clin Pract 71 (5). 2018;8(11):e021889. Ercan O, Kostu B, Bakacak M, Aytac-Tohma Y, Coskun B, Avci F, et al. Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K (2015) Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. In this study, 5-hydroxymethyl tolterodine (5-HMT) which is the main active metabolite of fesoterodine, was used to determine the effect of combination with mirabegron, since fesoterodine itself is inactive and rapidly converted after absorption. 2017;36(7):1824–31. BMC Med Res Methodol. BJU Int. NCT02138747 (2018) A study to evaluate tolerability and participants’ preference between mirabegron and tolterodine extended release (ER) in participants with overactive bladder (OAB) (PREFER). Neurourol Urodyn. Neurourol Urodyn, vol 34. You can also search for this author in Find out about Lean Library If you have access to journal via a society or associations, read the instructions belowAccess to society journal content varies across our titles.If you have access to a journal via a society or association membership, please browse to your society journal, select an article to view, and follow the instructions in this box.Contact us if you experience any difficulty logging in.Some society journals require you to create a personal profile, then activate your society accountYou are adding the following journals to your email alertsDid you struggle to get access to this article?